{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T04:08:49Z","timestamp":1773374929488,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jctejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical & Translational Endocrinology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jcte.2025.100403","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T12:05:18Z","timestamp":1750680318000},"page":"100403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["SGLT2 inhibitor therapy in overweight and obese patients with cystic fibrosis-related diabetes: Case series"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9520-0455","authenticated-orcid":false,"given":"Ammar","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roshini","family":"Asirvatham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jagdeesh","family":"Ullal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Moheet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcte.2025.100403_b0005","unstructured":"https:\/\/www.cff.org\/medical-professionals\/cystic-fibrosis-related-diabetes-clinical-care-guidelines."},{"issue":"8","key":"10.1016\/j.jcte.2025.100403_b0010","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/pedi.13453","article-title":"ISPAD Clinical Practice Consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents","volume":"23","author":"Ode","year":"2022","journal-title":"Pediatr Diabetes"},{"issue":"3","key":"10.1016\/j.jcte.2025.100403_b0015","first-page":"246","article-title":"Consensus report on nutrition for pediatric patients with cystic fibrosis","volume":"35","author":"Borowitz","year":"2002","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"7","key":"10.1016\/j.jcte.2025.100403_b0020","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jand.2020.03.014","article-title":"Effect of CFTR modulators on anthropometric parameters in individuals with cystic fibrosis: an evidence analysis center systematic review","volume":"121","author":"Bailey","year":"2021","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.jcte.2025.100403_b0025","unstructured":"Patient registry annual data report. 2021: Cystic fibrosis foundation."},{"issue":"1","key":"10.1016\/j.jcte.2025.100403_b0030","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12933-022-01455-2","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis","volume":"21","author":"Salah","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"10.1016\/j.jcte.2025.100403_b0035","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jdiacomp.2015.07.011","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years","volume":"29","author":"Liu","year":"2015","journal-title":"J Diabetes Complications"},{"issue":"1","key":"10.1016\/j.jcte.2025.100403_b0040","doi-asserted-by":"crossref","first-page":"17231","DOI":"10.1038\/s41598-017-17404-z","article-title":"Structural abnormalities in islets from very young children with cystic fibrosis may contribute to cystic fibrosis-related diabetes","volume":"7","author":"Bogdani","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jcte.2025.100403_b0045","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jcf.2013.02.008","article-title":"Update on cystic fibrosis-related diabetes","volume":"12","author":"Kelly","year":"2013","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcte.2025.100403_b0050","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/15513818609025923","article-title":"Pancreatic islets in older patients with cystic fibrosis with and without diabetes mellitus: morphometric and immunocytologic studies","volume":"6","author":"Soejima","year":"1986","journal-title":"Pediatr Pathol"},{"issue":"6","key":"10.1016\/j.jcte.2025.100403_b0055","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0022-3476(97)70282-8","article-title":"Insulin resistance is associated with decreased clinical status in cystic fibrosis","volume":"130","author":"Hardin","year":"1997","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.jcte.2025.100403_b0060","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/0884533613507086","article-title":"Malnutrition in cystic fibrosis: a review","volume":"28","author":"Culhane","year":"2013","journal-title":"Nutr Clin Pract"},{"issue":"5","key":"10.1016\/j.jcte.2025.100403_b0065","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review","volume":"108","author":"Stallings","year":"2008","journal-title":"J Am Diet Assoc"},{"issue":"3 Pt 1","key":"10.1016\/j.jcte.2025.100403_b0070","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0022-3476(98)70025-3","article-title":"Nutrition intervention for weight gain in cystic fibrosis: a meta analysis","volume":"132","author":"Jelalian","year":"1998","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.jcte.2025.100403_b0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jcf.2019.12.002","article-title":"Nutritional excess in cystic fibrosis: the skinny on obesity","volume":"19","author":"Litvin","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcte.2025.100403_b0080","article-title":"Glucagon-like peptide-1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: a case series and literature review","volume":"38","author":"Ahmed","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"issue":"1","key":"10.1016\/j.jcte.2025.100403_b0085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2215\/CJN.04010609","article-title":"Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target","volume":"5","author":"Santer","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.jcte.2025.100403_b0090","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diab Vasc Dis Res"},{"issue":"22","key":"10.1016\/j.jcte.2025.100403_b0095","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jcte.2025.100403_b0100","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jcte.2025.100403_b0105","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.jcte.2025.100403_b0110","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"S1","key":"10.1016\/j.jcte.2025.100403_b0115","first-page":"10","article-title":"SGLT2 inhibitors and weight loss in diabetes","volume":"23","author":"Fioretto","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.jcte.2025.100403_b0120","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.jcte.2025.100403_b0125","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/dom.12742","article-title":"Lack of evidence for a causal relationship between SGLT2 inhibitors and fracture risk: a meta-analysis of randomized controlled trials","volume":"18","author":"Tang","year":"2016","journal-title":"Diabetes Obes Metab"}],"container-title":["Journal of Clinical & Translational Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623725000213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214623725000213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:20:17Z","timestamp":1760336417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214623725000213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":25,"alternative-id":["S2214623725000213"],"URL":"https:\/\/doi.org\/10.1016\/j.jcte.2025.100403","relation":{},"ISSN":["2214-6237"],"issn-type":[{"value":"2214-6237","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitor therapy in overweight and obese patients with cystic fibrosis-related diabetes: Case series","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical & Translational Endocrinology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcte.2025.100403","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100403"}}